Molecule
Bepotastine is a histamine-1 receptor antagonist indicated for the treatment of itching associated with signs and symptoms of allergic conjunctivitis. It is available as eye drops and ophthalmic solution. MedsAcross supplies Bepotastine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Bepotastine Besilate Ophthalmic Solution, 1.5% is a histamine H 1 receptor antagonist indicated for the treatment of itching associated with signs and symptoms of allergic conjunctivitis. Bepotastine Besilate Ophthalmic Solution is a histamine H1 receptor antagonist indicated for the treatment of itching associated with allergic conjunctivitis.
Source: US FDA prescribing information
Bepotastine is a topically active, direct H1-receptor antagonist and an inhibitor of the release of histamine from mast cells.
Source: US FDA prescribing information
Instill one drop of Bepotastine Besilate Ophthalmic Solution into the affected eye(s) twice a day. Remove contact lenses prior to instillation of Bepotastine Besilate Ophthalmic Solution. Instill one drop into the affected eye(s) twice a day.
Source: US FDA prescribing information
Bepotastine Besilate Ophthalmic Solution is contraindicated in patients with a history of hypersensitivity reactions to bepotastine or any of the other ingredients. Hypersensitivity to any component of this product.
Source: US FDA prescribing information
Contamination of Solution: Do not touch the dropper tip to any surface. Keep bottle tightly closed when not in use. Contact Lens Wear: Bepotastine Besilate Ophthalmic Solution should not be used to treat contact lens-related irritation.
Source: US FDA prescribing information
The most common adverse reaction occurring in approximately 25% of patients was a mild taste following instillation. Other adverse reactions which occurred in 2-5% of subjects were eye irritation, headache, and nasopharyngitis.
Source: US FDA prescribing information
Store at 15°C to 25°C (59°F to 77°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Bepotastine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Bepotastine 15 mg/mL eye dropsOphthalmicGeneric name | — | US FDA | Available on request |
| Bepreve 15 mg/mL eye dropsOphthalmic | Bausch & Lomb | US FDA | Available on request |
| Bepotastine 15 mg/mL ophthalmic solutionOphthalmicGeneric name | — | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 8 September 2009 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 3 presentations of Bepotastine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Bepotastine, including Bepreve.
Yes. The US FDA first approved Bepotastine on 8 September 2009, according to Drugs@FDA.
No listed presentation of Bepotastine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.